MedTrace Logo

Changes in Liver Function After Stereotactic Body Radiation Therapy Measured by PET/CT

NCT01213758 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 14

Last updated 2017-10-30

No results posted yet for this study

Summary

Patients treated with stereotactic radiotherapy for liver tumors undergo PET/CT using the galactose analogue 18-F-deoxy-galactose (FDGal) before and after radiotherapy. This technique provides volumetric mapping of liver function and it allows quantisation of liver function. The method may be used for selection of patients for stereotactic radiotherapy of liver tumors, for determination of radiation induced liver dysfunction and may be included into the treatment planning process of stereotactic radiotherapy.

Conditions

Interventions

OTHER

Measuring liver function by PET/CT

Measuring liver function by use of FDGal and PET/CT before, 1 month and 3 months after stereotactic radiotherapy for liver tumors

Sponsors & Collaborators

  • Danish Cancer Society

    collaborator OTHER

  • University of Aarhus

    lead OTHER

Principal Investigators

  • Morten Høyer, MD PhD · Aarhus University Hospital

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-06-30
Primary Completion
2016-04-30
Completion
2016-04-30

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01213758 on ClinicalTrials.gov